Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050752 · ClinicalTrials.gov registry record
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
A clinical trial of Kidney Cancer and Renal Tumor Histology, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 1,130
- Enrollment target
- 1
- Study location
NCT00050752 is a study of Kidney Cancer and Renal Tumor Histology that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,130 participants, above the 862-participant average among 60 other Kidney Cancer trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00050752, a study of Kidney Cancer and Renal Tumor Histology, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 1,130 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try to determine: * What gene changes (mutations) cause HLRCC * What kind of kidney tumors develop in HLRCC and how they grow * What the chance is that a person with HLRCC will develop a kidney tumor People with known or suspected HLRCC (and their family members of any age) may be eligible for this study. This includes people in families in which one or more members has skin leiomyoma and kidney cancer; skin leiomyoma and uterine leiomyoma; multiple skin leiomyomas; kidney cancer and uterine leiomyomas, or kidney cancer consistent with HLRCC, including, but not limited to, collecting duct or papillary, type II. Candidates will be screened with a physical examination, family history, and, for affected family members, a review of medical records, including pathology slides and computed tomography (CT) or magnetic resonance imaging (MRI) scans. Participants will undergo tests and procedures that may include the following: * Review of medical records, x-rays, and tissue slides * Physical examination and family history * Skin examination * Gynecological examination for women * Interviews with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor * Blood tests for: 1. Genetic research to identify the gene responsible for HLRCC 2. Evaluation of liver, kidney, heart, pancreas, and thyroid function 3. Complete blood count and clotting profile 4. Pregnancy test for pre-menopausal women 5. PSA test for prostate cancer in men over age 40 * CT or MRI scans (for p
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,130 participants |
| Start Date | 2003-02-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050752
The ClinicalTrials.gov registry entry for NCT00050752 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 862-participant average among 60 other Kidney Cancer trials with a reported enrollment target (31% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00050752 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00050752 about?
NCT00050752 is a clinical study titled "Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer". This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people de...
What is the current status of trial NCT00050752?
This trial is currently recruiting. The enrollment target is 1,130 participants. The study started on 2003-02-24.
What conditions does trial NCT00050752 study?
This clinical trial studies the following conditions: Kidney Cancer, Renal Tumor Histology, Cutaneous Leiomyoma.
Who is sponsoring clinical trial NCT00050752?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00050752 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
RECRUITING · NA
-
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
RECRUITING
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RECRUITING
-
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
RECRUITING
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.